HRTX
HEALTHCAREHeron Therapeutics Inc
$1.31+0.08 (+6.50%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving HRTX Today?
No stock-specific AI insight has been generated for HRTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.74$2.30
$1.31
Fundamentals
Market Cap$247M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-24.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume4.6M
Avg Volume (10D)—
Shares Outstanding188.6M
HRTX News
20 articles- Ironwood Pharmaceuticals (IRWD) Tops Q1 Earnings and Revenue EstimatesYahoo Finance·May 7, 2026
- electroCore, Inc. (ECOR) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to DeclineYahoo Finance·May 6, 2026
- Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out forYahoo Finance·May 4, 2026
- Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026Yahoo Finance·Apr 27, 2026
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarYahoo Finance·Apr 8, 2026
- How to Boost Your Portfolio with Top Medical Stocks Set to Beat EarningsYahoo Finance·Apr 7, 2026
- Heron Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Feb 26, 2026
- Heron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ...Yahoo Finance·Feb 26, 2026
- Heron Therapeutics Q4 Earnings Call HighlightsMarketbeat·Feb 26, 2026
- Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to SayYahoo Finance·Feb 26, 2026
- Heron Therapeutics: Q4 Earnings SnapshotYahoo Finance·Feb 26, 2026
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial ResultsYahoo Finance·Feb 26, 2026
- Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026Yahoo Finance·Feb 17, 2026
- Breakeven Is Near for Heron Therapeutics, Inc. (NASDAQ:HRTX)Yahoo Finance·Jan 25, 2026
- Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83MYahoo Finance·Jan 10, 2026
- Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 GrowthYahoo Finance·Jan 9, 2026
- Heron Therapeutics, Inc. (NASDAQ:HRTX) is favoured by institutional owners who hold 57% of the companyYahoo Finance·Dec 15, 2025
- Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)Yahoo Finance·Dec 4, 2025
- Heron Therapeutics (HRTX): Forecasts Signal 60.89% Annual Earnings Growth, Path to Profitability in FocusYahoo Finance·Nov 5, 2025
All 20 articles loaded
Price Data
Open$1.23
Previous Close$1.23
Day High$1.24
Day Low$1.19
52 Week High$2.30
52 Week Low$0.74
52-Week Range
$0.74$2.30
$1.31
Fundamentals
Market Cap$247M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-24.1%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume4.6M
Avg Volume (10D)—
Shares Outstanding188.6M
About Heron Therapeutics Inc
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—